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Abstract
Introduction: Statins (hydroxymethylglutaryl coenzyme A reductase inhibitors) are effective in reducing the risk of
cardiovascular morbidity and mortality in patients with hyperlipidemia, hypertension, or type II diabetes. Next to
their cholesterol-lowering activity, statins have immunomodulatory properties. Based on these properties, we
hypothesized that statin use may eventually lead to dysregulation of immune responses, possibly resulting in
autoimmunity. We have recently shown in an observational study that statin use was associated with an increased
risk of developing rheumatoid arthritis. Our objective was to investigate whether a causal relationship could be
established for this finding.
Methods: The mouse collagen type II (CII)-induced arthritis (CIA) model was used, with immunization, challenge,
and euthanasia at days 0, 21, and 42, respectively. Statins were given orally before (day -28 until day 21) or after
(day 21 until day 42) CIA induction. Atorvastatin (0.2 mg/day) or pravastatin (0.8 mg/day) was administered.
Arthritis was recorded three times a week. Serum anti-CII autoantibodies and cytokines in supernatants from
Concanavalin-A-stimulated lymph node cells and CII-stimulated spleen cells were measured.
Results: Statin administration accelerated arthritis onset and resulted in 100% arthritic animals, whereas only seven
out of 12 nonstatin control animals developed arthritis. Atorvastatin administration after CIA induction resulted in
earlier onset than atorvastatin administration before induction, or than pravastatin administration before or after
induction. The arthritic score of animals given pravastatin before CIA induction was similar to that of the nonstatin
controls, whereas the other groups that received statins showed higher arthritic scores. Atorvastatin administration,
especially before CIA induction, increased anti-CII autoantibody production. IL-2 and IL-17 production by lymph
node and spleen cells was higher in CIA animals than in PBS controls, but was not affected by statin
administration. While IFNg production was not affected by CIA induction, atorvastatin administration before CIA
induction increased the production of this cytokine.
Conclusion: These data support previous results from our observational studies, indicating a role for statins in the
induction of autoimmunity.
Introduction
Statins (hydroxymethylglutaryl coenzyme A reductase
inhibitors) have been shown to be effective in reducing
the risk of cardiovascular morbidity and mortality in
patients with hyperlipidemia, hypertension, or type II
diabetes [1-4]. In addition to their cholesterol-lowering
activity, several studies have shown that statins have
anti-inflammatory and immunomodulatory properties
[5-8]. We hypothesized that because of these immuno-
modulatory properties statin use may eventually lead to
dysregulation of immune responses, possibly resulting in
autoimmunity. In line with this hypothesis, we have
recently shown in an observational study that statin use
was associated with an increased risk of developing
rheumatoid arthritis (RA) [9]. Moreover, based on indi-
vidual case reports we found a positive association
between statin use and the occurrence of lupus-like syn-
drome [10]. This latter association was recently con-
firmed by another research group [11].
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To investigate whether a causal relationship can be
established for these observations, we evaluated the
effects of statin administration on arthritis in the col-
lagen type II (CII)-induced arthritis (CIA) mouse model.
In this model for RA, mice are immunized with CII
mixed with Freund’s complete adjuvant, and are chal-
lenged 3 weeks later with CII alone. Arthritis is scored
from the time of challenge onwards [12].
Several studies have shown beneficial effects of statin
administration on joint inflammation in the mouse CIA
model [13-16]. However, these studies did not specifically
address the effects of statin administration before arthri-
tis induction, an issue that follows from our observational
study [9]. Nonetheless, to relate our results to the animal
studies indicated above [13-16], we also evaluated effects
of statin administration after arthritis induction.
Here we show that statin administration accelerated
arthritis onset and resulted in 100% arthritic animals,
whereas only seven out of 12 nonstatin control animals
developed arthritis. Atorvastatin administration after CIA
induction resulted in earlier onset than atorvastatin
administration before induction, or than pravastatin
administration before or after induction. The arthritic
score of animals given pravastatin before CIA induction
was similar to that of the nonstatin controls, whereas the
other groups that received statins showed higher arthritic
scores. Atorvastatin administration, especially before CIA
induction, increased anti-CII autoantibody production.
IL-2 and IL-17 production by lymph node (LN) and
spleen cells was not affected by statin administration.
Atorvastatin administration before CIA induction
increased IFNg production.
Materials and methods
Induction and assessment of collagen-induced arthritis
Male DBA/1OlaHsd mice were obtained from Harlan
(Horst, the Netherlands). At the age of 10 to 12 weeks
the animals were injected intradermally at the base of the
tail with 100 μl of an emulsion of bovine CII (Chondrex,
Redmond, WA, USA) and Freund’s complete adjuvant
(Chondrex) on day 0 (final concentrations of CII and
Freund’s complete adjuvant, 1 mg/ml). The mice were
challenged by intraperitoneal injection of 100 μl CII (con-
centration 1 mg/ml) on day 21. Body weight and arthritis
severity were assessed three times per week in a blinded
manner, using a semiquantitative scoring system (with
scores ranging from 0 to 4 for each paw) until the mice
were euthanized on day 42 [12]. Arthritis scoring was
performed by two individuals, alternating between days;
there were no visible systematic differences in the way
they scored. Mice were anesthetized with ketamine, rom-
pun, and atropine, and blood was collected from the
orbital plexus. Inguinal LNs of the hind paws and the
spleens were excised.
The animal experiments were approved prior to their
commencement by an independent ethical committee,
in accordance with national legislation.
Statin administration
Atorvastatin (calcium salt) was a kind gift from Pfizer
(Groton, CT, USA). Pravastatin (sodium salt) was obtained
from Teva (Debrecen, Hungary). Atorvastatin (1 mg/ml)
and pravastatin (4 mg/ml) were administered daily by oral
gavage (0.2 ml). The atorvastatin dose approximates
10 mg/kg body weight [17]. The lipid-lowering and lipo-
protein-lowering efficacy of pravastatin is four times lower
than that of atorvastatin [18], and pravastatin was thus
given at a four times higher concentration than atorvasta-
tin. Atorvastatin and pravastatin were given either before
challenge (day -28 until day 20) or after challenge (day 22
until day 42; see Figure 1). PBS (0.2 ml) was given as a
control on days when statins were not administered. One
control group received only PBS, and a second control
group (negative control) received only PBS and arthritis
was not induced. These groups received 0.2 ml PBS by
oral gavage daily throughout the experiment. There were
12 mice per group.
Measurement of autoantibodies
Anti-bovine CII IgG antibodies were measured using an
ELISA (mouse anti-bovine CII IgG assay kit; Chondrex)
according to the manufacturer’s instructions. Briefly,
after incubation with blocking buffer, a serial dilution of
the standard as well as a 20,000-fold dilution of serum
samples was incubated. After incubation with peroxi-
dase-conjugated goat anti-mouse IgG, O-phenylenedia-
mine dihydrochloride was added, the reaction was
stopped, and the optical density was measured at
490 nm. The plates were washed before and between all
incubation steps.
Cell culture
The culture medium used was RPMI-1640 (Gibco,
Grand Island, NY, USA) supplemented with 10% FCS,
100 μg/ml streptomycin, and 100 IU/ml penicillin. Cell
suspensions were made by pressing the LNs and spleens
through a cell strainer (Falcon, Franklin Lakes, NJ,
USA). Cells were counted using a Coulter Counter
(Coulter Electronics, Luton, UK). LN cell suspensions
were cultured at 106 cells/ml culture medium with 5 μg/
ml Concanavalin A (MP Biomedicals, Irvine, CA, USA)
in 96-well tissue culture plates (Nunc, Roskilde, Den-
mark) for 24 hours. Spleen cell suspensions were cul-
tured at 106 cells/ml culture medium with 50 μg/ml CII
or 5 μg/ml Concanavalin A in 96-well tissue culture
plates (Nunc) for 72 hours. Culture conditions were
37°C in a humidified atmosphere containing 5% carbon
dioxide.
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Cytokine measurements
A 10-plex panel containing beads for mouse IL-1*, IL-2,
IL-4, IL-6, IL-10, IL-12p70, IL-17, granulocyte-macro-
phage colony-stimulating factor, IFNg, and TNF* (Bio-
Rad, Hercules, CA, USA) was used. After incubation
and washing steps [19], the beads were measured on a
Bio-Plex (Bio-Rad).
Statistical analysis of arthritis induction
We analyzed the fraction of animals with arthritis as a
function of time, by fitting time-response models to our
data. We used PROAST, a general program for dose-
response modeling [20,21]. These models apply directly by
regarding time rather than dose as the independent vari-
able - that is, the time of onset of arthritis defined as the
median time when 50% of the animals develop arthritis
(ET50)). The fitted model was the log-logistic model:
y = a + (1 − a) / {1 + exp [c ln (b/x)]}
where y is the fraction of animals showing arthritis
and x is the time (a, b and c are constants). First, the
model was fitted to the data from all (five) experimental
groups combined - that is, the same ET50 value was esti-
mated for all treatment groups. The same model was
then fitted but now by estimating a treatment-specific
ET50 value. When the associated fit of the model (as
reflected by the value of the log-likelihood) is signifi-
cantly improved (likelihood ratio test), this indicates a
significant treatment effect on the ET50 value.
The analysis of the fraction of animals with arthritis over
time as described above is statistically invalid because the
observations over time relate to the same animals (that is,
the assumption of independent observations does not
hold). As a result, P values and confidence intervals of the
means will be too optimistic. We therefore performed an
additional analysis as follows. The arthritis severity scores
were analyzed as a function of time using a so-called
latent-variable model. In this model the latent variable
reflects the arthritis severity as a continuously increasing
value with time, while the observed scores are imagined to
arise from consecutive cutoff values on that underlying
continuous severity scale. These cutoff values are esti-
mated while fitting the time-response model to the scores
[22]. The latent-variable model:
y = a exp (b × d)
where y is the latent variable and x is time (a, b and d
are constants), was fitted to the observed scores for all
individuals combined, by including the factor individual
animal as a covariate. Individuals were found to signifi-
cantly differ in the time-response curve regarding para-
meter b, but parameters a and d were not found to
differ significantly. Hence, we fitted the model with only
parameter b dependent on the individual animal. The
resulting estimates for b were then analyzed in a one-
way analysis of variance to compare the treatments. In
this analysis the estimates for b are statistically indepen-
dent. Because the results of statin treatments on arthritis
induction using the latent variable model were similar to
the results using the log-likelihood model, we have cho-
sen to show the results of the latter model.
General statistical analysis
The effect of arthritis induction on body weight, autoan-
tibody production, and cytokine production was assessed
using an independent-samples t test (SPSS Inc., Chicago,
IL, USA). The effect of statin treatments on body
weight, autoantibody production and cytokine produc-
tion was assessed using one-way analysis of variance,
followed by the Bonferroni post hoc test (SPSS Inc.).
Results
Body weight
Induction of CIA resulted in a lower body weight com-
pared with negative control animals (Figure 2). This dif-
ference was statistically significant (P < 0.05) from day 33
Figure 1 Scheme of collagen-induced arthritis induction and statin administration. Mice were immunized at day 0 (IMM) and challenged
at day 21 (CHA), after which arthritis was scored three times a week until day 42. Atorvastatin (A) or pravastatin (P) were given daily, either
before (day -28 until day 20) or after (day 22 until day 42) collagen-induced arthritis (CIA) induction. Mice were euthanized at day 42.
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after immunization onwards. Atorvastatin administration
before CIA induction resulted in a lower body weight
compared with CIA control animals (Figure 2). This dif-
ference was statistically significant (P < 0.05) from day 37
after immunization onwards. Atorvastatin administration
after CIA induction, or pravastatin administration before
or after CIA induction, did not significantly alter body
weight compared with CIA control animals.
Arthritis
Statin administration (both atorvastatin and pravastatin,
both before and after CIA induction) resulted in 100%
arthritic animals at the time of euthanasia, whereas only
seven out of 12 nonstatin control animals had developed
arthritis at that time point (Figure 3A). Statin administra-
tion resulted in earlier arthritis onset, expressed as the day
after immunization in which 50% of the animals show
arthritis (Figure 4). Atorvastatin administration after CIA
induction resulted in earlier onset than atorvastatin
administration before CIA induction, or than pravastatin
administration before or after CIA induction (Figure 4).
The arthritic score summed per group of animals
showed a similar score for the animals that received pra-
vastatin before CIA induction and nonstatin controls,
whereas the other groups of statin-administered animals
showed higher scores (Figure 3B). Only seven out of 12
nonstatin controls became arthritic, so the mean arthritic
score for animals that received pravastatin before CIA
induction was lower than for the nonstatin controls (data
not shown).
Autoantibody production
Induction of CIA resulted in the presence of anti-CII anti-
bodies (log IgG level = 5.17; P < 0.001 compared with the
negative controls). Atorvastatin administration resulted in
higher anti-CII antibody production compared with pra-
vastatin administration and the CIA control (P = 0.005
and P = 0.013, respectively). In addition, atorvastatin
administration before CIA induction increased the anti-
CII antibody production compared with the CIA control
(P < 0.05; Figure 5).
Cytokine production
Induction of CIA resulted in increased IL-2 production
by Concanavalin-A-stimulated LN cells and increased IL-
2 and IL-17 production by CII-stimulated spleen cells (P
< 0.05; Figure 6). For none of the other cytokines tested
was a significant effect due to CIA induction found.
Atorvastatin administration after CIA induction
increased IFNg production by CII-stimulated spleen
Figure 2 Effect of collagen-induced arthritis induction and statin treatment on body weight. Mice were immunized at day 0, challenged
at day 21, and weighed three times a week until euthanasia at day 42. Statins were given daily. Black circles connected by dotted line,
atorvastatin before collagen-induced arthritis (CIA) induction; black squares connected by dotted line, atorvastatin after CIA induction; black
triangles connected by dotted line, pravastatin before CIA induction; black inverted triangles connected by dotted line, pravastatin after CIA
induction; black diamonds connected by dotted line, CIA control; black circles connected by continuous line, negative control. n = 12 per group.
The effect of arthritis induction was assessed using an independent-samples t test; the effect of statin treatments was assessed using one-way
analysis of variance, followed by the Bonferroni post hoc test.
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cells (P < 0.05; Figure 6). Combining the results of both
statins, administration after but not before CIA induc-
tion resulted in increased production (P < 0.01). Com-
bining the results of both time points, both atorvastatin
and pravastatin increased IFNg production (P < 0.05).
For none of the other cytokines tested was a significant
effect due to statin administration found.
Figure 3 Effect of statin treatment on arthritis incidence and
score. (A) Number of arthritic animals per group versus time after
immunization. (B) Summed arthritis score per group of animals
versus time after immunization. Mice were immunized at day 0 and
challenged at day 21, after which arthritis was scored three times a
week until day 42. Statins were given daily. Black circles connected
by dotted line, atorvastatin before collagen-induced arthritis (CIA)
induction; black squares connected by dotted line, atorvastatin after
CIA induction; black triangles connected by dotted line, pravastatin
before CIA induction; black inverted triangles connected by dotted
line, pravastatin after CIA induction; black diamonds connected by
continuous line, CIA control. n = 12 per group.
Figure 4 Statin administration accelerates arthritis onset
(fraction of arthritic animals versus time). Mice were immunized
at day 0 and challenged at day 21, after which arthritis was scored
three times a week until day 42. (A) Mice were given atorvastatin
before challenge (day -28 until day 20, pre-A; cross sign, dark blue
line) or after challenge (day 22 until day 42, post-A; open triangle,
red line), or they were given pravastatin before challenge (pre-P;
plus sign, green line) or after challenge (post-P; open circle, black
line). Control mice (open diamond, light blue line) did not receive
statins. The dark blue and black lines are overlapping. (B) Median
time when 50% of the animals develop arthritis (ET50 values; mean
and 90% confidence intervals), calculated from (A). *Significantly
different (P < 0.05) from control mice; +significantly different (P <
0.05) from pre-A, pre-P, and post-P treated mice. n = 12 per group.
ET50 values (mean and 90% confidence intervals) were calculated
using the PROAST program [20,21]. One-way analysis of variance,
followed by the Bonferroni post hoc test.
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Figure 5 Anti-collagen type II IgG levels. Mice were immunized at day 0 and challenged at day 21. Atorvastatin (A) or pravastatin (P) were
given daily, either before (day -28 until day 20) or after (day 22 until day 42) collagen-induced arthritis induction. Mice were euthanized at day
42. Control mice (C) did not receive statins. Anti-collagen type II (anti-CII) IgG was measured in serum by ELISA. *Significantly different (P < 0.05)
from C. n = 12 per group. One-way analysis of variance, followed by the Bonferroni post hoc test.
Figure 6 Cytokine production by lymph node and spleen cells. (A) IL-2 production by Concanavalin-A (Con A)-stimulated inguinal lymph
node (LN) cells. (B) IL-2 production by collagen type II (CII)-stimulated spleen cells. (C) IL-17 production by CII-stimulated spleen cells. (D) IFNg
production by CII-stimulated spleen cells. Mice were immunized at day 0 and challenged at day 21. Atorvastatin (A) or pravastatin (P) were given
daily, either before (day -28 until day 20) or after (day 22 until day 42) collagen-induced arthritis induction. Mice were euthanized at day 42.
Control mice (C) did not receive statins. In negative mice (N), arthritis was not induced and these mice did not receive statins. Inguinal LNs were
excised and LN cells were cultured in the presence of Con A for 24 hours. Spleens were excised and spleen cells were cultured in the presence
of CII for 72 hours. Cytokine content was measured in the supernatants. n = 12. *Significantly different (P < 0.05) from N; +significantly different
(P < 0.05) from C. n = 12 per group. The effect of arthritis induction was assessed using an independent-samples t test; the effect of statin
treatments was assessed using one-way analysis of variance, followed by the Bonferroni post hoc test.
Vandebriel et al. Arthritis Research & Therapy 2012, 14:R90
http://arthritis-research.com/content/14/2/R90
Page 6 of 10
Discussion
Here we have shown that statin administration results in
100% arthritic animals, whereas only seven out of 12
nonstatin control animals developed arthritis. Moreover,
statin administration accelerated arthritis onset. This
accelerated onset was seen when statin administration
was started either before or after CIA induction. Acceler-
ated onset resulting from statin administration before
CIA induction is in line with our hypothesis of statin-
induced immune deviation resulting in autoimmunity
[9,10]. In addition, we observed that atorvastatin admin-
istration after CIA induction resulted in earlier arthritis
induction than administration with the same statin
before CIA induction. Overall, atorvastatin had a some-
what stronger effect on accelerating onset than pravasta-
tin. Atorvastatin administration before or after CIA
induction, or pravastatin administration after CIA induc-
tion, resulted in a similar mean arthritic score compared
with the nonstatin control, while pravastatin administra-
tion before CIA induction resulted in a lower mean
arthritic score. In this latter pravastatin group the accel-
eration of arthritis onset was 5 days, while that in the
other cases was 7 or 9 days. This lower mean arthritic
score may suggest a beneficial effect of pravastatin. This
dosing regime, however, also results in accelerated arthri-
tis onset and an increased number of arthritic animals.
Other studies using the mouse CIA model have shown
beneficial effects of statin administration on joint inflam-
mation [13-16]. To establish whether statin type, dose,
route of administration, or timing of administration rela-
tive to CIA induction influenced the clinical outcome,
the results of the above-mentioned studies as well as our
data are compared in Table 1. Suppression of arthritis
development was seen after oral administration of 10
mg/kg atorvastatin (the same exposure route and dose as
we used in our study) during (almost) the whole period
from immunization to euthanasia [13]. This finding con-
trasts our results that show accelerated onset when 10
mg/kg atorvastatin was given orally either before or after
CII challenge. This issue needs to be resolved in future
studies. Suppression of arthritis development was also
found after intraperitoneal administration of 100 mg/kg
pravastatin [14] or 40 mg/kg simvastatin [15,16]. Using
other statins, lower doses, or other exposure routes failed
to show an effect on arthritis. An accelerated onset of
arthritis was only found in our study.
Atorvastatin administration before CIA induction
resulted in increased anti-CII antibody production,
whereas atorvastatin administration after CIA induction
resulted in a nonsignificant increase in production of
this antibody. Pravastatin administration before and
after CIA induction, however, did not affect anti-CII
IgG antibody production.
Atorvastatin administration before CIA induction
resulted in accelerated arthritis onset and increased
autoantibody production. This observation may suggest
that increased autoantibody production plays a role in
accelerated arthritis onset. Our observational study
showed that statin use is associated with an increased
risk of developing RA [9]. In humans, IgM rheumatoid
factor and anti-cyclic citrullinated peptide antibodies
have been found years before RA becomes clinically
apparent [23]. For RA patients that used statins before
developing clinically manifest disease, therefore, statin
Table 1 Comparison of statin effects on murine collagen-induced arthritis
Study Statin Dose (mg/kg) Exposure route Timing (days) Effect on arthritis
Present study A 10 Oral -28 to 20 ΔET50 -7 days
Present study A 10 Oral 22 to 42 ΔET50 -9 days
Present study P 40 Oral -28 to 20 ΔET50 -5 days
Present study P 40 Oral 22 to 42 ΔET50 -7 days
Ho and colleagues [13] A 10 Oral 2 to 49 Suppression
Yamagata and colleagues [14] P 100 Intraperitoneal 0 to 35 Suppression
Leung and colleagues [15] S 40 Intraperitoneal 21 to 40 Suppression
Leung and colleagues [15] S 20 Intraperitoneal 21 to 40 No effect
Leung and colleagues [15] S 10 Intraperitoneal 21 to 40 No effect
Palmer and colleagues [16] A 100 Oral 0 to 48 No effect
Palmer and colleagues [16] A 1 Oral 0 to 48 No effect
Palmer and colleagues [16] R 2 Subcutaneous 0 to 48 No effect
Palmer and colleagues [16] R 0.2 Subcutaneous 0 to 48 No effect
Palmer and colleagues [16] R 40 Intraperitoneal 21 to 35 No effect
Palmer and colleagues [16] S 40 Intraperitoneal 21 to 35 Suppression
Palmer and colleagues [16] S 40 Oral 21 to 35 No effect
A, atorvastatin; P, pravastatin; S, simvastatin; R, rosuvastatin; ΔET50, number of days between the time when 50% of the animals developed arthritis (ET50 value)
for the statin-treated animals and the ET50 value for the control animals.
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use may have coincided with autoantibody development.
Statins may be speculated to increase autoantibody pro-
duction, thereby facilitating RA development.
CIA induction resulted in increased IL-2 production
by Concanavalin-A-stimulated LN cells, probably reflect-
ing the stronger activation or higher frequency of T cells
in the LN draining the inflamed joints. Production of
this cytokine was not significantly affected by statin
administration. Similarly, CIA induction resulted in
increased IL-2 production by CII-stimulated spleen cells,
and production of IL-2 was not significantly affected by
statin administration.
Furthermore, CIA induction resulted in increased IL-
17 production by CII-stimulated spleen cells. Since IL-
23-deficient mice that lack IL-17-producing CD4+ cells
(Th17 cells) are resistant to CIA induction [24], Th17
cells are assumed to play an essential role in CIA. The
activation or frequency of Th17 cells in the spleen is
probably increased in arthritic mice, in line with pre-
vious studies [24-27]. Importantly, IL-17 production was
not significantly affected by statin administration.
In addition, CIA induction resulted in decreased IFNg
production by LN cells (0.75-fold) and CII-stimulated
spleen cells (0.71-fold), albeit not statistically signifi-
cantly (data not shown). Since IFNg acts as a disease-
limiting factor in CIA [28], reduced levels of this cyto-
kine may possibly be characteristic for CIA. Since ator-
vastatin was shown to inhibit IFNg production [29], and
absence of IFNg signaling resulted in accelerated arthri-
tis onset [30,31], reduced production of this cytokine
may be a possible mechanism underlying accelerated
arthritis onset due to atorvastatin treatment. We did
not, however, observe altered IFNg production due to
statin administration. Taking together the IL-17 and
IFNg data, the increased IL-17 and decreased IFNg pro-
duction upon CIA induction fits the selective induction
of Th17 and not T-helper type 1 cells in CIA [24].
Another possible mechanism by which statins may
affect arthritis is through their induction of caspase-1,
IL-1b, and IL-18 in monocytes, resulting in increased
IFNg production by T cells [32]. Interestingly, this
increased IFNg production occurred only at low statin
concentrations. Caspase-1 activation results in cleavage
of pro-IL-1b and pro-IL-18 to their mature (active)
forms. Caspase-1, IL-1b, and IL-18 are all implicated in
CIA. The pharmacologic caspase-1 inhibitor VX-765
reduced paw inflammation when given as a prophylactic
and a therapeutic [33]. IL-1b administration accelerated
arthritis [34], while anti-IL-1b treatment markedly sup-
pressed established arthritis [35]. IL-18 administration
resulted in higher arthritis incidence and severity
[36,37], while IL-18-deficient mice showed reduced
arthritis incidence and severity [38]. This observation
may suggest that statins aggravate arthritis by activating
caspase-1, thereby inducing IL-1b and IL-18. Increased
IFNg production may, on the contrary, reduce arthritis.
Taking the two possible mechanisms together, caspase-1
activation by statins may aggravate arthritis by inducing
IL-1b and IL-18. The resulting IFNg induction that in
itself reduces arthritis may be counteracted by the T-
helper type 2 skewing effect of statins. Clearly, disease
outcome results from a complicated interplay between
various effects of statins. In our hands, statin exposure
resulted in accelerated arthritis onset.
In summary, the anti-CII antibody, IL-2, IL-17, and
IFNg data do not provide a possible mechanism for the
accelerated arthritis observed in this study. It should be
noted, however, that establishing such a mechanism was
not the aim of our study. We aimed to investigate
whether a causal relationship could be established for
the association between statin use and an increased risk
of developing RA.
The CIA model was chosen because our observational
study has shown that statin use was associated with an
increased risk of developing RA [9]; because it is a
model for RA, recapitulating many aspects of the disease
[39-42]; because an induced model is preferred to a
spontaneous model, since only in an induced model can
the effects of statin use prior to expression of arthritis
be tested; and because the mouse CIA model is both B-
cell and T-cell mediated and is therefore more similar
to human RA than models such as the rat adjuvant
arthritis model, which is (only) T-cell mediated.
Conclusions
Here we have shown that administration of atorvastatin
and pravastatin resulted in accelerated arthritis onset in
a mouse CIA model. Atorvastatin administration after
CIA induction resulted in earlier onset than atorvastatin
administration before CIA induction, or than pravastatin
administration before or after CIA induction. Atorvasta-
tin administration, especially before CIA induction,
resulted in increased autoantibody production. Impor-
tantly, our data provide a causal relationship for pre-
vious results obtained from observational studies [9,10].
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